Johnson & Johnson has reported positive results for its Phase III FUZION study of its Tremfya (guselkumab) therapy for Crohn’s disease.  

The findings show that Tremfya maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease. Johnson & Johnson state the findings, which are being presented at the 2026 United European Gastroenterology Week (UEG Week), support the use of Tremfya in one of the most difficult-to-treat manifestations of CD.  

Key findings from the Phase III study in Crohn’s disease with perianal fistula 

Findings show that combined fistula remission was maintained or improved in both Tremfya maintenance regimens through Week 48. At 100mg given every eight weeks, combined fistula remission further increased from 28% at Week 24 to 35% at Week 48.  

Results among patients receiving Tremfya at 200mg every four weeks remained consistent through Week 48.  

“Perianal fistula remain one of the most debilitating complications of Crohn’s disease, where achieving durable disease control beyond symptom improvement is a challenge,” said Dr Laurent Peyrin-Biroulet,  study investigator. “The latest findings from the FUZION study, which is the first of its kind in 20 years, shows that patients treated with Tremfya maintained or improved upon the clinical benefits observed at Week 24, providing encouraging evidence for its use in this patient population.” 

“These one-year findings expand the evidence for Tremfya in perianal fistulising Crohn’s disease where long-term treatment options remain limited,” said Dr David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson. “Building on our longstanding expertise in immune-mediated diseases, we are committed to studying Tremfya across the full spectrum of moderately to severely active Crohn’s disease and generating evidence that may transform outcomes for patients, including those facing some of its most challenging complications.”